Skip to main content

Closed

CYTK: Cytokinetics, Incorporated Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+145.3% / yr

Operating margin-605.1%

ROIC-56.2%

Financially safe

Stretched

Debt / equity-1.56×

Interest coverage-5.6×

Current ratio4.21×

Cytokinetics, Incorporated

CYTKNASDAQ·USD·Closed

Cytokinetics, Incorporated

CYTKNASDAQ·USD·Closed

$77.13

−4.09%

$77.13

−$3.29 (4.09%)

52W Range

80thpctl

Volume

0.59×avg

Mkt Cap

9.60BUSD

P/E

-11.3TTM

Div Yield

–ann

52W Range

80thpctl

Volume

0.59×avg

Market Cap

9.60BUSD

P/E Ratio

-11.3TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings